Autopsy report · NCT00660062

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

“Slow inclusion”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 5 years 3 months before it stopped.
• 47 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Hillerod Hospital, Denmark

Sponsor type

University, hospital or other

Conditions

Major Depression

Interventions

escitalopram; escitalopram; escitalopram; nortriptyline

Participants

47

Sites

1

Countries

Denmark

Trials that died the same way

• Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients
  “Inclusion curve too slow.” (77% match in meaning)
• PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?
  “Inclusion rate too slow / infeasible.” (75% match in meaning)
• Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
  “Because of inclusion delay” (71% match in meaning)
• Biochemical Makers for Outcome After Pediatric out-of Hospital Cardiac Arrest
  “Low inclusion rate” (70% match in meaning)
• Tamsulosin for Urinary Retention in Hospitalized Older Women
  “low inclusion” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.